<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H1664632B27C2409EA51BE883B20C318D" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2597 IH: Accelerating Innovation in Medicine Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-06-01</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2597</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150601">June 1, 2015</action-date>
			<action-desc><sponsor name-id="P000594">Mr. Paulsen</sponsor> (for himself, <cosponsor name-id="K000188">Mr. Kind</cosponsor>, <cosponsor name-id="S000364">Mr. Shimkus</cosponsor>, and <cosponsor name-id="W000820">Mrs. Mimi Walters of California</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend title XVIII of the Social Security Act to promote health care technology innovation and
			 access to medical devices and services for which patients choose to
			 self-pay under the Medicare program, and for other purposes.</official-title>
	</form>
	<legis-body id="H858DD19310104D9292D40740694B6A63" style="OLC">
 <section id="H587CD9C0798E494291374D85EA2F93B7" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Accelerating Innovation in Medicine Act of 2015</short-title></quote> or the <quote><short-title>AIM Act of 2015</short-title></quote>.</text> </section><section id="H2EE113CE70D04AC3B61037759FDA30E4"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds as follows:</text>
 <paragraph id="H346BCE6C941F464593E03F50159BD78E"><enum>(1)</enum><text>Innovation in health care technology is necessary to improve health outcomes and depends in part on the ability of medical technology developers, including scientists, physicians, engineers, and patient advocates, to introduce medical devices into the marketplace.</text>
 </paragraph><paragraph id="H908C8E0117BD400C8C954F70F6A88987"><enum>(2)</enum><text>Even after meeting requirements for marketing set by the Food and Drug Administration, there may be uncertainties about patient access through Government health care programs, causing significant delays in bringing innovative medical devices to patients or causing medical technology developers to abandon potential health care solutions.</text>
 </paragraph><paragraph id="H0EFAFDB48FB34C39A515E1D686D0909C"><enum>(3)</enum><text>Patients covered by the Medicare program are often willing to enter into self-pay arrangements with physicians and other providers to purchase items or services, yet under current laws restricting such freedom of choice, the self-pay arrangements may be associated with regulatory impediments or a risk of civil penalties.</text>
 </paragraph><paragraph id="HFD3615E78832432ABDA8376B329C9F0B"><enum>(4)</enum><text>Enabling health care technology manufacturers to designate products to be directly available to self-pay patients and excluded from Government health program payments at an early stage of product development will promote innovation and result in increased patient access to desired products and services, save taxpayer dollars, and reduce administrative burdens on physicians and the Government.</text>
 </paragraph><paragraph id="H1C751D31609F41C980BF4867BDA48ED4"><enum>(5)</enum><text>Enabling health care technology manufacturers to designate their devices as available to self-pay patients would permit a window of time during which additional data may be obtained on outcomes, comparative clinical effectiveness or other data elements for possible future coverage by the Medicare program.</text>
			</paragraph></section><section id="HFDCC5550C1D94F6DB3CBC228CF46CD81"><enum>3.</enum><header>Establishment of manufacturer opt-out program for medical devices</header>
 <subsection id="H53A2B771930F4E7BB9692EE40094BAE3"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1862 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y</external-xref>) is amended adding at the end the following new subsection:</text>
				<quoted-block id="H7843FF55A690416CA07732E756BCBCC4" style="OLC">
					<subsection id="H38D64419443843D18E4AB8DDDFBCC27C"><enum>(p)</enum><header>Establishment of accelerating innovation in medicine (AIM) list of medical devices voluntarily
			 excluded from coverage</header>
 <paragraph id="H441D37786D2A43D99C65CAC621DA86BC"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 90 days after the date of the enactment of this subsection, the Secretary shall develop and maintain a listing (in this section referred to as the <quote>AIM list</quote>) of medical devices for which, because of their inclusion in such listing, no insurance benefit and no payment may be made for such a device under this title either directly or on a capitated basis such that no claim for payment may be submitted under this title for such a device and an individual who consents to receive such a device is responsible for payment for the device and services related to furnishing the device.</text>
						</paragraph><paragraph id="HE1680595ED3B4EE8A111A582CE591802"><enum>(2)</enum><header>Procedures for inclusion in AIM list</header>
 <subparagraph id="H78F1644623C94EEEA1333113856EB26B"><enum>(A)</enum><header>Requirement for written consent of manufacturer</header><text>No medical device may be included in the AIM list without the written consent of the manufacturer of the device.</text>
 </subparagraph><subparagraph id="HD37C74B121A540C8A7DAF363FB01446C"><enum>(B)</enum><header>Submission process</header><text display-inline="yes-display-inline">A manufacturer seeking to have a medical device included in the AIM list shall submit to the Secretary a request for inclusion of the device in the AIM list. In the case of such a device for whichâ€”</text>
 <clause id="H58DD23A646BA4BD289054871A01DC9CA"><enum>(i)</enum><text display-inline="yes-display-inline">there is a request for approval or clearance for marketing and sale of the device by the Food and Drug Administration pursuant to authority granted by the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>), including pursuant to section 510(k) or 515(c) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(k)</external-xref>, 360e(c)), the request for inclusion of the device in the AIM list may not be submitted earlier than the date of the request for such approval or clearance and no later than the first business day of the month beginning at least 30 days after the date of such approval or clearance; or</text>
 </clause><clause id="HA955BB24D4DA470D9D5A0B7AF85230A9"><enum>(ii)</enum><text display-inline="yes-display-inline">the device is exempt from such approval and clearance requirements, the request may be submitted at a time that is not later than the first business day of the month beginning at least 30 days after the date of the first sale of the device by its manufacturer.</text>
								</clause></subparagraph></paragraph><paragraph id="H23EBD2EBA11742FCAE798F677AAE97EF"><enum>(3)</enum><header>Listing periods; removal from list</header>
 <subparagraph id="HD48A6B52B7B0484CA7A4374D723040A3"><enum>(A)</enum><header>3-year listing periods</header><text>A medical device included in the AIM list shall be initially listed for a period of 3 years and shall remain so listed for subsequent 3-year periods subject to subparagraphs (B) and (C).</text>
 </subparagraph><subparagraph id="H3CC1A4AC3B01418D988A0BA60CFB6C3C"><enum>(B)</enum><header>Removal at request of manufacturer</header><text display-inline="yes-display-inline">At any time a device of a manufacturer included in the AIM list shall be removed from the AIM list upon the written request of the manufacturer. Subject to subparagraph (C), such a device of a manufacturer may not be removed from the AIM list except upon the written request of the manufacturer.</text>
 </subparagraph><subparagraph id="H3FB97D2CABC04347A917A2CEC529001C"><enum>(C)</enum><header>Provision of data on clinical studies as a condition for continued listing</header><text display-inline="yes-display-inline">As a condition for the continued inclusion of the device of a manufacturer in the AIM list for a subsequent 3-year listing period under subparagraph (A), the manufacturer shall provide the Secretary with published or publicly available data on clinical studies completed for the device at the end of the previous 3-year listing period. If the Secretary determines that a manufacturer of a device has materially failed to provide such data for the device, the Secretary may remove the device from the AIM list or not renew the listing for the device or both.</text>
 </subparagraph></paragraph><paragraph id="HC2A57C30CD764970BF7791E952FE5B3F"><enum>(4)</enum><header>Medical device defined</header><text>In this subsection, the term <term>medical device</term> has the meaning given the term <term>device</term> in section 201(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(h)</external-xref>).</text> </paragraph><paragraph id="H5DC6BC06F576497AA5F5754E51DB481B"><enum>(5)</enum><header>Posting of listed devices on website</header><text>The Secretary shall post on a public website of the Department of Health and Human Services or other publicly accessible manner a list of the medical devices included in the AIM list and shall provide for updating the website on a real-time basis (but no less frequently than monthly) to reflect changes in the medical devices in the AIM list.</text>
 </paragraph><paragraph id="H79607A873994491681C52EC0B5D653F0"><enum>(6)</enum><header>Regulations not required</header><text>Nothing in this subsection shall be construed as requiring the Secretary to promulgate regulations to carry out this subsection.</text>
 </paragraph><paragraph id="H6A84A1353DFE45DF9A1DFECDF516E713"><enum>(7)</enum><header>Requirement for informed consent in order for provider to charge for device</header><text display-inline="yes-display-inline">If a physician or other entity furnishes a medical device included in the AIM list to an individual under this title and failed to obtain, before furnishing the device, an appropriate informed consent under which the individual is informed of and accepts liability under paragraph (1) for payment for the device (and related services), the physician or other entity is deemed to have agreed not to impose any charge under this title for such device (and for services related to furnishing the device).</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="HE1EA9148B50D4EA68914C2096A526AEE"><enum>(b)</enum><header>Conforming amendment</header><text>Section 1862(a) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y(a)</external-xref>) is amendedâ€”</text> <paragraph id="HA1DB5EFBA4A14C81B670D160A60BAAA1"><enum>(1)</enum><text>in paragraph (24), by striking <quote>or</quote> at the end;</text>
 </paragraph><paragraph id="H733BEF1C600941068D568350C364AB15"><enum>(2)</enum><text>in paragraph (25), by striking the period at the end and inserting <quote>; or</quote>; and</text> </paragraph><paragraph id="HEA0C03996AD9470FB2E55D4B8E8DDA3F"><enum>(3)</enum><text>by inserting after paragraph (25) the following new paragraph:</text>
					<quoted-block id="HFBA56D0BAFC34D438EDEFB650A384282" style="OLC">
 <paragraph id="H9F25325720CA4B41819A510FB0B8135E"><enum>(26)</enum><text>where such expenses are for a medical device included in the AIM list under section 1862(p) or for items and services related to furnishing such device.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection></section></legis-body>
</bill>


